Skip to Main Content

Author Details

Syed Haider
Institute of Cancer Research
2002
125
44
PMIDPaper TitleJournal TitlePublished Year
37801608Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.Cancer Res2024
36914817Age-associated microenvironmental changes highlight the role of PDGF-C in ER<sup>+</sup> breast cancer metastatic relapse.Nat Cancer2023
37635223Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer.J Exp Clin Cancer Res2023
37524790SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.Nat Genet2023
37587096Implications of tumour heterogeneity on cancer evolution and therapy resistance: lessons from breast cancer.J Pathol2023
37574209Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).Clin Cancer Res2023
37973922Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype.Nat Commun2023
37280675Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer.J Exp Clin Cancer Res2023
37180510Biopsy-Proven Renal-Limited Thrombotic Microangiopathy in a Heart Transplant Recipient.Kidney Int Rep2023
37163373MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.Cell Rep2023
34741135Functional annotation of breast cancer risk loci: current progress and future directions.Br J Cancer2022
35764612Liver glycogen phosphorylase is upregulated in glioblastoma and provides a metabolic vulnerability to high dose radiation.Cell Death Dis2022
35749591Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade.Cancer Res2022
36273494SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance.Cancer Res2022
36161312Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.Clin Cancer Res2022
34921020Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis.Clin Cancer Res2022
35127740Investigations on Zinc Isotope Fractionation in Breast Cancer Tissue Using <i>in vitro</i> Cell Culture Uptake-Efflux Experiments.Front Med (Lausanne)2022
35205651Characterisation of the Stromal Microenvironment in Lobular Breast Cancer.Cancers (Basel)2022
35053458Assessment of the Molecular Heterogeneity of E-Cadherin Expression in Invasive Lobular Breast Cancer.Cancers (Basel)2022
35017538Age influences on the molecular presentation of tumours.Nat Commun2022
33028955Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer.Br J Cancer2021
33674617Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment.NPJ Breast Cancer2021
335099443D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.Cancer Res2021
33837305Identifying high-confidence capture Hi-C interactions using CHiCANE.Nat Protoc2021
34750509Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency.Commun Biol2021
34681953ELTD1 Activation Induces an Endothelial-EMT Transition to a Myofibroblast Phenotype.Int J Mol Sci2021
33964942Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation.J Exp Clin Cancer Res2021
34146516Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element.Am J Hum Genet2021
34359755Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma.Cancers (Basel)2021
34140467Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.Nat Commun2021
34112782Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis.Nat Commun2021
33972745Predicting the clinical outcome of oral potentially malignant disorders using transcriptomic-based molecular pathology.Br J Cancer2021
33435284The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing.J Clin Med2021
32699032Clinical <i>BRCA1/2</i> Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance.Cancer Discov2020
31755096Real-time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study.J Pathol2020
31819193Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin.Br J Cancer2020
32909943SOX11 promotes epithelial/mesenchymal hybrid state and alters tropism of invasive breast cancer cells.Elife2020
32908313Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer.Nature2020
33015524Systematic Assessment of Tumor Purity and Its Clinical Implications.JCO Precis Oncol2020
32759235Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.J Immunother Cancer2020
30300715Workforce Analysis of Spine Surgeons Involved with Neurological and Orthopedic Surgery Residency Training.World Neurosurg2019
31775252ADGRL4/ELTD1 Silencing in Endothelial Cells Induces ACLY and SLC25A1 and Alters the Cellular Metabolic Profile.Metabolites2019
31259422The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.J Pathol2019
31308365Landscape of transcriptomic interactions between breast cancer and its microenvironment.Nat Commun2019
30885992Adaptation to HIF1α Deletion in Hypoxic Cancer Cells by Upregulation of GLUT14 and Creatine Metabolism.Mol Cancer Res2019
30268556Academic Productivity of Spine Surgeons at United States Neurological Surgery and Orthopedic Surgery Training Programs.World Neurosurg2019
304781493D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers.Mol Cancer Ther2019
30589644PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.J Clin Invest2019
30447010Non-canonical activation of CREB mediates neuroprotection in a Caenorhabditis elegans model of excitotoxic necrosis.J Neurochem2019
30665349BPG: Seamless, automated and interactive visualization of scientific data.BMC Bioinformatics2019
  • 1 - 50 of 125

Recommended Authors

Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 4
Siyuan Zheng
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 11
Yang Xie
Quantitative Biomedical Research Center
Career Start Year 2007
Number of shared co-authors 3
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 30
Matti Nykter
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 19
Nathalie Pochet
Broad Institute of MIT and Harvard
Career Start Year 2004
Number of shared co-authors 0
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 16
Andrew V Kossenkov
The Wistar Institute
Career Start Year 2003
Number of shared co-authors 2
Leslie Cope
Johns Hopkins University School of Medicine
Career Start Year 2003
Number of shared co-authors 4
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 16
Amy G Robertson
Present address: Dxige Research Inc.
Career Start Year 2003
Number of shared co-authors 16
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 2
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 16
Mikhail G Dozmorov
Virginia Commonwealth University
Career Start Year 2001
Number of shared co-authors 1
Yidong Chen
The University of Texas Health Science Center at San Antonio
Career Start Year 2001
Number of shared co-authors 1
Andrea Sboner
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 17
Yan W Asmann
Mayo Clinic
Career Start Year 2000
Number of shared co-authors 3
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 50
Celine Lefebvre
The Scripps Research Institute
Career Start Year 1999
Number of shared co-authors 0
Paul T Spellman
Oregon Health & Science University Hospital.
Career Start Year 1998
Number of shared co-authors 33
Benedikt Brors
German Cancer Research Center (DKFZ)
Career Start Year 1997
Number of shared co-authors 21
Lianbo Yu
The Ohio State University
Career Start Year 1997
Number of shared co-authors 3
Dongquan Chen
University of Alabama at Birmingham
Career Start Year 1997
Number of shared co-authors 1
Sudhir Varma
Center for Cancer Research, National Cancer Institute
Career Start Year 1994
Number of shared co-authors 4
Samuel Aparicio
University of British Columbia
Career Start Year 1993
Number of shared co-authors 17
Adam B Olshen
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 2
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 48
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 11
Eivind Hovig
Center for Bioinformatics, University of Oslo
Career Start Year 1987
Number of shared co-authors 15

Collaborators

Paul C Boutros
University of California los angeles
Co-authored papers 25
Adrian L Harris
University of Oxford
Co-authored papers 23
Francesca M Buffa
University of Oxford
Co-authored papers 14
Francis Nguyen
Ontario Institute for Cancer Research
Co-authored papers 9
Damian Smedley
William Harvey Research Institute, Queen Mary University of London
Co-authored papers 8
Arek Kasprzyk
European Bioinformatics Institute (EBI)
Co-authored papers 8
Maud H W Starmans
Ontario Institute for Cancer Research
Co-authored papers 8
Pietro Li??
University of Cambridge
Co-authored papers 7
Philippe Lambin
Maastricht University
Co-authored papers 7
Clare M Isacke
Co-authored papers 6
Emilie Lalonde
University of Pennsylvania
Co-authored papers 6
Cindy Q Yao
Ontario Institute for Cancer Research
Co-authored papers 6
Natalie S Fox
University of California los angeles
Co-authored papers 5
Bradly G Wouters
Princess Margaret Cancer Centre, University Health Network and, University of Toronto
Co-authored papers 5
Paul Flicek
European Bioinformatics Institute
Co-authored papers 5
Richard Durbin
University of Cambridge
Co-authored papers 4
Tim Hubbard
Co-authored papers 4
Clement Fung
Ontario Institute for Cancer Research
Co-authored papers 4
Michelle Chan-Seng-Yue
Princess Margaret Cancer Centre
Co-authored papers 4
Damian Keefe
University of Adelaide
Co-authored papers 4
Kenneth C Chu
Ontario Institute for Cancer Research
Co-authored papers 4
Stefan Gr??f
Heart and Lung Research Institute, University of Cambridge
Co-authored papers 4
Michael Schuster
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
Co-authored papers 4
Daryl Waggott
Ontario Institute for Cancer Research
Co-authored papers 4
Stephen M J Searle
Wellcome Trust Sanger Institute
Co-authored papers 4
Jianxin Wang
Ontario Institute for Cancer Research
Co-authored papers 4
Fiona Cunningham
European Bioinformatics Institute
Co-authored papers 4
Richard Holland
Eagle Genomics Ltd
Co-authored papers 4
Karyn Megy
University of Cambridge
Co-authored papers 4
Arek Kasprzyk
Ontario Institute for Cancer Research
Co-authored papers 4
Release 1.2